Baxter International (BAX) Projected to Post Quarterly Earnings on Thursday

Baxter International (NYSE:BAX) is expected to post its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $0.60 per share and revenue of $2.8774 billion for the quarter. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS.Investors may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.01). Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The business had revenue of $2.81 billion for the quarter, compared to analysts’ expectations of $2.82 billion. During the same period in the previous year, the company earned $0.68 EPS. Baxter International’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, analysts expect Baxter International to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Baxter International Price Performance

Shares of NYSE:BAX opened at $22.92 on Thursday. The company has a quick ratio of 1.49, a current ratio of 2.30 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $11.77 billion, a PE ratio of -76.38, a price-to-earnings-growth ratio of 0.74 and a beta of 0.58. The firm’s 50 day moving average price is $23.49 and its 200-day moving average price is $27.21. Baxter International has a twelve month low of $21.33 and a twelve month high of $37.74.

Institutional Investors Weigh In On Baxter International

Large investors have recently made changes to their positions in the company. MUFG Securities EMEA plc purchased a new stake in shares of Baxter International in the second quarter worth about $46,000. BI Asset Management Fondsmaeglerselskab A S increased its stake in Baxter International by 21.4% in the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,356 shares of the medical instruments supplier’s stock worth $737,000 after acquiring an additional 4,293 shares during the last quarter. Baird Financial Group Inc. raised its holdings in shares of Baxter International by 3.2% during the 2nd quarter. Baird Financial Group Inc. now owns 52,436 shares of the medical instruments supplier’s stock worth $1,588,000 after acquiring an additional 1,604 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of Baxter International by 5.5% during the 2nd quarter. Captrust Financial Advisors now owns 53,933 shares of the medical instruments supplier’s stock valued at $1,633,000 after acquiring an additional 2,813 shares during the last quarter. Finally, California State Teachers Retirement System grew its holdings in shares of Baxter International by 2.9% in the second quarter. California State Teachers Retirement System now owns 649,463 shares of the medical instruments supplier’s stock valued at $19,666,000 after purchasing an additional 18,439 shares in the last quarter. 90.19% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on BAX. Citigroup dropped their price target on shares of Baxter International from $34.00 to $32.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 9th. The Goldman Sachs Group cut Baxter International from a “buy” rating to a “neutral” rating and set a $25.00 target price on the stock. in a report on Friday, August 1st. Evercore ISI cut their price target on Baxter International from $33.00 to $31.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Wall Street Zen downgraded Baxter International from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Wells Fargo & Company lowered their price objective on Baxter International from $33.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $28.89.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.